Template:Hormone levels with oral estradiol

• v
• t
• e

Hormone levels with oral estradiol

• 
  Estradiol levels after a single oral dose of 2, 4, or 8 mg estradiol in premenopausal women.^[1]
• 
  Estradiol and estrone levels following a single 2 mg dose of oral estradiol in postmenopausal women.^[2]
• 
  Mean estradiol levels during 1 to 8 mg/day oral estradiol therapy alone or in combination with 100 to 200 mg/day spironolactone in transgender women.^[3]
• 
  Percent change in estradiol (E2), estrone (E1), LH, and FSH levels over a 24-hour period following a single dose of 2 mg oral estradiol in women.^[4][5]
• 
  Levels of estradiol, estrone, and estrone sulfate following a single 2 mg oral dose of estradiol valerate in postmenopausal women.^[6][7][8]
• 
  Estradiol levels after a single dose of 2 mg oral estradiol or 2 mg oral estradiol valerate and with continuous administration of 2 mg/day oral estradiol or 2 mg/day oral estradiol valerate (at steady state) in postmenopausal women.^[9]

Template documentation

See also

• Pharmacokinetics of estradiol § Oral administration

References

1. Kuhnz W, Gansau C, Mahler M (September 1993). "Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol". Arzneimittelforschung. 43 (9): 966–73. ISSN 0004-4172. PMID 8240460.
2. Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (December 2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–16. doi:10.1097/GME.0000000000000467. PMC 4666011. PMID 25944519.
3. Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgend Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC 5944393. PMID 29756046.
4. Yen SS, Martin PL, Burnier AM, Czekala NM, Greaney MO, Callantine MR (March 1975). "Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17beta-estradiol in postmenopausal women". J. Clin. Endocrinol. Metab. 40 (3): 518–21. doi:10.1210/jcem-40-3-518. PMID 1117058.
5. Quirk, J. Gerald; Wendel, George D. (1983). "Biologic Effects of Natural and Synthetic Estrogens". In J.J. Buchsbaum (ed.). The Menopause. pp. 55–75. doi:10.1007/978-1-4612-5525-3_5. ISBN 978-1-4612-5525-3. ISSN 0178-0328.
6. Aedo AR, Landgren BM, Diczfalusy E (November 1990). "Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women". Maturitas. 12 (4): 333–43. doi:10.1016/0378-5122(90)90013-v. PMID 2124648.
7. Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
8. Kuhl, H. (1998). "Pharmakologie von Sexualsteroiden". Der Gynäkologe. 31 (10): 832. doi:10.1007/s001290050341. ISSN 0017-5994. S2CID 20941492.
9. Wiegratz I, Fink T, Rohr UD, Lang E, Leukel P, Kuhl H (September 2001). "Überkreuz-Vergleich der Pharmakokinetik von Estradiol unter der Hormonsubstitution mit Estradiolvalerat oder mikronisiertem Estradiol" [Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol]. Zentralbl Gynakol (in German). 123 (9): 505–12. doi:10.1055/s-2001-18223. PMID 11709743.

Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages.
Subpages of this template.